首页> 外文期刊>Molecular medicine reports >Analysis of somatic mutations in BRAF, CDKN2A/p16 and PI3KCA in patients with medullary thyroid carcinoma
【24h】

Analysis of somatic mutations in BRAF, CDKN2A/p16 and PI3KCA in patients with medullary thyroid carcinoma

机译:甲状腺髓样癌患者BRAF,CDKN2A / p16和PI3KCA的体细胞突变分析

获取原文
获取原文并翻译 | 示例
           

摘要

Medullary thyroid carcinoma (MTC), a neuroendocrine tumor originating from thyroid parafollicular cells, has been demonstrated to be associated with mutations in RET, HRAS, KRAS and NRAS. However, the role of other genes involved in the oncogenesis of neural crest tumors remains to be fully investigated in MTC. The current study aimed to investigate the presence of somatic mutations in BRAF, CDKN2A and PI3KCA in MTC, and to investigate the correlation with disease progression. DNA was isolated from paraffin-embedded tumors and blood samples from patients with MTC, and the hotspot somatic mutations were sequenced. A total of 2 novel HRAS mutations, p.Asp33Asn and p.His94Tyr, and polymorphisms within the 3' untranslated region (UTR) of CDKN2A (rs11515 and rs3088440) were identified, however, no mutations were observed in other genes. It was suggested that somatic point mutations in BRAF, CDKN2A and PI3KCA do not participate in the oncogenesis of MTC. Further studies are required in order to clarify the contribution of the polymorphisms identified in the 3' UTR of CDKN2A in MTC.
机译:甲状腺髓样癌(MTC)是一种源自甲状腺滤泡旁细胞的神经内分泌肿瘤,已被证实与RET,HRAS,KRAS和NRAS突变相关。但是,其他基因参与神经rest肿瘤的肿瘤发生的作用仍有待在MTC中进行充分研究。当前的研究旨在调查MTC中BRAF,CDKN2A和PI3KCA体细胞突变的存在,并研究其与疾病进展的相关性。从石蜡包埋的肿瘤和MTC患者的血液样本中分离DNA,并对热点体细胞突变进行测序。总共鉴定出2个新的HRAS突变p.Asp33Asn和p.His94Tyr,以及CDKN2A的3'非翻译区(UTR)内的多态性(rs11515和rs3088440),但是在其他基因中未观察到突变。有人提出BRAF,CDKN2A和PI3KCA中的体细胞点突变不参与MTC的致癌作用。为了阐明在MTC中CDKN2A的3'UTR中鉴定的多态性的贡献,需要进一步的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号